瑞巴派特联合伊托必利、雷贝拉唑治疗反流性食管炎的临床观察

Clinical observation of rebamipide combined with itopride and rabeprazole in the treatment of reflux esophagitis

目的观察瑞巴派特联合伊托必利、雷贝拉唑治疗反流性食管炎的临床疗效。方法将150例反流性食管炎患者随机分为治疗组和对照组,每组75例。对照组给予伊托必利联合雷贝拉唑治疗,治疗组在对照组治疗的基础上加用瑞巴派特治疗,比较2组治疗4周后的临床疗效。结果 2组治疗前症状积分比较差异无统计学意义(P>0.05);2组治疗后症状积分均明显降低,且治疗组低于对照组,差异均有统计学意义(P<0.05)。2组治疗前血清胃泌素水平比较差异无统计学意义(P>0.05);2组治疗后血清胃泌素水平均明显升高,且治疗组高于对照组,差异均有统计学意义(P<0.05)。2组治疗前24 h内食管pH<4的总时间百分比比较差异无统计学意义(P>0.05);2组治疗后24 h内食管pH<4的总时间百分比均降低,且治疗组低于对照组,差异均有统计学意义(P<0.05)。结论瑞巴派特联合伊托必利、雷贝拉唑可明显改善反流性食管炎的临床症状,提高血清胃泌素水平,降低食管内pH值,值得临床推广应用。

Objective To observe the clinical efficacy of rebamipide combined with itopride and rabeprazole in the treatment of reflux esophagitis. Methods 150 patients with reflux esophagitis were randomly divided into treatment group and control group. The control group（ 75 cases） was treated with itopride and rabeprazole,and the treatment group（ 75 cases） was treated with rebamipide on the basis of the control group,the clinical efficacy of the two groups after 4 weeks of treatment was compared. Results There was no significant difference in the scores of symptom scores between the two groups before treatment（ P〉0. 05）. The symptom scores of the two groups were significantly lower after treatment,and the treatment group was lower than the control group,the difference was statistically significant（ P〈0. 05）. There was no significant difference in serum gastrin levels between the two groups before treatment（ P〉0. 05）. The levels of serum gastrin were significantly increased in the 2 groups after treatment,and the treatment group was higher than the control group,the difference was statistically significant（ P〈0. 05）. There was no significant difference in the percentage of total time of esophageal pH 4 within 24 hours before treatment（ P〉0. 05）. The percentage of total time of esophageal pH 〈4 within 24 hours after treatment in both groups decreased,and the treatment group was lower than the control group,the difference was statistically significant（ P〈0. 05）. Conclusion Rebamipide combined with itopride and rabeprazole can significantly improve the clinical symptoms of reflux esophagitis,increase serum gastrin levels,and lower the esophageal pH value,and it is worthy of clinical application.